Format

Send to

Choose Destination
Toxicol Sci. 2016 Jun;151(2):214-23. doi: 10.1093/toxsci/kfw038. Epub 2016 Mar 28.

Rat Urinary Osteopontin and Neutrophil Gelatinase-Associated Lipocalin Improve Certainty of Detecting Drug-Induced Kidney Injury.

Author information

1
*Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut 06877.
2
Merck and Co, Inc, Summit, New Jersey 07901.
3
GlaxoSmithKline, King of Prussia, Pennsylvania 19406.
4
Sanofi, Vitry-sur-Seine, 94400 France.
5
Critical Path Institute, Tucson, Arizona 85718.
6
AbbVie, North Chicago, Illinois 60064.
7
Janssen Research and Development, San Diego, California 92116.
8
Eli Lilly and Company Indianapolis, Indiana 46285.
9
Summit Therapeutics, Cambridge, Massachusetts 02142.
10
Novartis Pharmaceuticals, Basel, Switzerland.
11
Critical Path Institute, Tucson, Arizona 85718 ewalker@c-path.org.

Abstract

Traditional kidney biomarkers are insensitive indicators of acute kidney injury, with meaningful changes occurring late in the course of injury. The aim of this work was to demonstrate the diagnostic potential of urinary osteopontin (OPN) and neutrophil gelatinase-associated lipocalin (NGAL) for drug-induced kidney injury (DIKI) in rats using data from a recent regulatory qualification submission of translational DIKI biomarkers and to compare performance of NGAL and OPN to five previously qualified DIKI urinary biomarkers. Data were compiled from 15 studies of 11 different pharmaceuticals contributed by Critical Path Institute's Predictive Safety Testing Consortium (PSTC) Nephrotoxicity Working Group (NWG). Rats were given doses known to cause DIKI or other target organ toxicity, and urinary levels of the candidate biomarkers were assessed relative to kidney histopathology and serum creatinine (sCr) and blood urea nitrogen (BUN).OPN and NGAL outperformed sCr and BUN in identifying DIKI manifested as renal tubular epithelial degeneration or necrosis. In addition, urinary OPN and NGAL, when used with sCr and BUN, increased the ability to detect renal tubular epithelial degeneration or necrosis. NGAL and OPN had comparable or improved performance relative to Kim-1, clusterin, albumin, total protein, and beta-2 microglobulin. Given these data, both urinary OPN and NGAL are appropriate for use with current methods for assessing nephrotoxicity to identify and monitor DIKI in regulatory toxicology studies in rats. These data also support exploratory use of urinary OPN and NGAL in safety monitoring strategies of early clinical trials to aid in the assurance of patient safety.

KEYWORDS:

drug development tool qualification; drug-induced kidney injury; letter of support.; neutrophil gelatinase-associated lipocalin (NGAL); osteopontin (OPN); urinary safety biomarker

PMID:
27026710
DOI:
10.1093/toxsci/kfw038
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center